Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M HORWITZ

Showing results (581-590 of 831) with videos related to

Pageof 84
Sort By:
Head & Neck|February 19, 2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer, Eric M Horwitz, Jonathan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
Journal of Thrombosis and Haemostasis : JTH|October 30, 2024
Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody productionElizabeth S York, Benjamin D Dratch, Jasmine Ito, et al.
International Journal of Radiation Oncology, Biology, Physics|November 26, 2010
American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancerSeth A Rosenthal, Nathan H J Bittner, David C Beyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Haematologica|July 18, 2024
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T-cell lymphomasNatasha E Lewis, Kseniya Petrova-Drus, Rohan Sardana, et al.
American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.
Cytotherapy|October 10, 2023
Differential response of mesenchymal stromal cells (MSCs) to type 1 ex vivo cytokine priming: implications for MSC therapyAndre J Burnham, Elisabetta M Foppiani, Kyndal L Goss, et al.
Journal of the American Academy of Dermatology|February 1, 2019
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skinMeenal K Kheterpal, Julia Dai, Shamir Geller, et al.
American Journal of Clinical Oncology|August 10, 2020
Pelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation TherapyJonathan J Paly, Mengying Deng, Charles T Lee, et al.
Pageof 84

Showing results (581-590 of 831) with videos related to

Sort By:
Pageof 84
Head & Neck|February 19, 2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer, Eric M Horwitz, Jonathan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
Journal of Thrombosis and Haemostasis : JTH|October 30, 2024
Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody productionElizabeth S York, Benjamin D Dratch, Jasmine Ito, et al.
International Journal of Radiation Oncology, Biology, Physics|November 26, 2010
American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancerSeth A Rosenthal, Nathan H J Bittner, David C Beyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Haematologica|July 18, 2024
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T-cell lymphomasNatasha E Lewis, Kseniya Petrova-Drus, Rohan Sardana, et al.
American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.
Cytotherapy|October 10, 2023
Differential response of mesenchymal stromal cells (MSCs) to type 1 ex vivo cytokine priming: implications for MSC therapyAndre J Burnham, Elisabetta M Foppiani, Kyndal L Goss, et al.
Journal of the American Academy of Dermatology|February 1, 2019
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skinMeenal K Kheterpal, Julia Dai, Shamir Geller, et al.
American Journal of Clinical Oncology|August 10, 2020
Pelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation TherapyJonathan J Paly, Mengying Deng, Charles T Lee, et al.
Pageof 84